ZOLMITRIPTAN TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ZOLMITRIPTAN

から入手可能:

JUBILANT GENERICS LIMITED

ATCコード:

N02CC03

INN（国際名）:

ZOLMITRIPTAN

投薬量:

2.5MG

医薬品形態:

TABLET

構図:

ZOLMITRIPTAN 2.5MG

投与経路:

ORAL

パッケージ内のユニット:

6

処方タイプ:

Prescription

治療領域:

SELECTIVE SEROTONIN AGONISTS

製品概要:

Active ingredient group (AIG) number: 0134381001; AHFS:

認証ステータス:

APPROVED

承認日:

2014-01-21

製品の特徴

_Zolmitriptan _
_Page 1 of 31 _
PRODUCT MONOGRAPH
PR
ZOLMITRIPTAN
Zolmitriptan
Tablets, 2.5 mg
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
SPONSOR: DATE OF REVISION:
Jubilant Generics Limited
March 27, 2020
1A- Sector 16A, Institutional Area,
Noida, Uttar Pradesh, India, 201301
DISTRIBUTOR:
Pharmapar Inc.,
1565 Boul. Lionel- Boulet, Varennes
QC J3X 1P7
SUBMISSION CONTROL NO.: 237077
_Zolmitriptan _
_Page 2 of 31 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...................................................
3
SUMMARY PRODUCT
INFORMATION.....................................................................
3
INDICATIONS AND CLINICAL
USE............................................................................
3
CONTRAINDICATIONS..................................................................................................
3
WARNINGS AND
PRECAUTIONS................................................................................
4
ADVERSE
REACTIONS..................................................................................................
10
DRUG
INTERACTIONS..................................................................................................
15
DOSAGE AND
ADMINISTRATION..............................................................................
17
OVERDOSAGE.................................................................................................................
18
ACTION AND CLINICAL
PHARMACOLOGY.............................................................
18
STORAGE AND
STABILITY..........................................................................................
20
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 20
PART II: SCIENTIFIC
INFORMATION..............................................................................
21
PHARMACEUTICAL
INFORMATION..........................................................................
21
CLINICAL
TRIALS.......................................................................................